Napredna pretraga

Pregled bibliografske jedinice broj: 1000731

Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA


(EuroSIDA study group) Amele, S; Peters, L; Sluzhynska, M; Yakovlev, A; Begovac, Josip; Machala, L; Sedlaček, Dalibor
Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA // Hiv medicine, 20 (2019), 4; 264-273 doi:10.1111/hiv.12711 (međunarodna recenzija, članak, znanstveni)


Naslov
Establishing a hepatitis C continuum of care among HIV/hepatitis C virus-coinfected individuals in EuroSIDA

Autori
Amele, S ; Peters, L ; Sluzhynska, M ; Yakovlev, A ; Begovac, Josip ; Machala, L ; Sedlaček, Dalibor

Kolaboracija
EuroSIDA study group

Izvornik
Hiv medicine (1464-2662) 20 (2019), 4; 264-273

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
Continuum of care ; Europe ; HIV/HCV coinfection ; sustained virological response ; treatment

Sažetak
Objectives The aim of the study was to establish a methodology for evaluating the hepatitis C continuum of care in HIV/hepatitis C virus (HCV)-coinfected individuals and to characterize the continuum in Europe on 1 January 2015, prior to widespread access to direct-acting antiviral (DAA) therapy. Methods Stages included in the continuum were as follows: anti-HCV antibody positive, HCV RNA tested, currently HCV RNA positive, ever HCV RNA positive, ever received HCV treatment, completed HCV treatment, follow-up HCV RNA test, and cure. Sustained virological response (SVR) could only be assessed for those with a follow-up HCV RNA test and was defined as a negative HCV RNA result measured > 12 or 24 weeks after stopping treatment. Results Numbers and percentages for the stages of the HCV continuum of care were as follows: anti-HCV positive (n = 5173), HCV RNA tested (4207 of 5173 ; 81.3%), currently HCV RNA positive (3179 of 5173 ; 61.5%), ever HCV RNA positive (n = 3876), initiated HCV treatment (1693 of 3876 ; 43.7%), completed HCV treatment (1598 of 3876 ; 41.2%), follow-up HCV RNA test to allow SVR assessment (1195 of 3876 ; 30.8%), and cure (629 of 3876 ; 16.2%). The proportion that achieved SVR was 52.6% (629 of 1195). There were significant differences between regions at each stage of the continuum (P < 0.0001). Conclusions In the proposed HCV continuum of care for HIV/HCV-coinfected individuals, we found major gaps at all stages, with almost 20% of anti-HCV-positive individuals having no documented HCV RNA test and a low proportion achieving SVR, in the pre-DAA era.

Izvorni jezik
Engleski



POVEZANOST RADA


Projekt / tema
108-1080116-0098 - Epidemiološka i klinička obilježja zaraze HIV-om u Hrvatskoj (Josip Begovac, )

Ustanove
Medicinski fakultet, Zagreb

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati